Patents by Inventor Julie L. Sutcliffe
Julie L. Sutcliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131206Abstract: The present disclosure provides methods and related compositions that incorporate a molecularly targeted approach via the integrin subtype ?v?6 using Peptide Receptor Radionuclide Therapy (PRRT) and a theranostic approach.Type: ApplicationFiled: December 3, 2021Publication date: April 25, 2024Applicant: The Regents of the University of CaliforniaInventor: Julie L. Sutcliffe
-
Publication number: 20240101601Abstract: The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.Type: ApplicationFiled: September 15, 2022Publication date: March 28, 2024Applicant: The Regents of the University of CaliforniaInventors: Sven H. Hausner, Julie L. Sutcliffe
-
Publication number: 20230183317Abstract: Provided herein are methods for detecting, monitoring, diagnosing and treating respiratory-related viral infections, including SARS-CoV-2 infected individuals and subjects that are infected with or suspected of having been infected with the virus, or that have come in contact with COVID-19 suffering individuals.Type: ApplicationFiled: November 4, 2022Publication date: June 15, 2023Applicant: The Regents of the University of CaliforniaInventor: Julie L. Sutcliffe
-
Patent number: 11591369Abstract: The present invention provides peptides and peptide-conjugates that bind to ?v?6 integrin. The peptide-conjugates can be used for a variety of imaging and therapeutic applications. Methods of use and peptide optimization are also provided herein.Type: GrantFiled: March 3, 2021Date of Patent: February 28, 2023Assignee: The Regents of the University of CaliforniaInventors: Yng Tang, Julie L. Sutcliffe
-
Patent number: 11485758Abstract: The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.Type: GrantFiled: December 22, 2020Date of Patent: November 1, 2022Assignee: The Regents of the University of CaliforniaInventors: Sven H. Hausner, Julie L. Sutcliffe
-
Publication number: 20220047730Abstract: The present invention provides peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates comprise a moiety such as a PEG moiety, an imaging agent, or a therapeutic agent. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue. Compositions and kits containing the peptide conjugates of the present invention are also provided herein.Type: ApplicationFiled: October 18, 2021Publication date: February 17, 2022Applicant: The Regents of the University of CaliforniaInventors: Yng Tang, Julie L. Sutcliffe
-
Patent number: 11185601Abstract: The present invention provides peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates comprise a moiety such as a PEG moiety, an imaging agent, or a therapeutic agent. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue. Compositions and kits containing the peptide conjugates of the present invention are also provided herein.Type: GrantFiled: December 12, 2018Date of Patent: November 30, 2021Assignee: The Regents of the University of CaliforniaInventors: Yng Tang, Julie L. Sutcliffe
-
Publication number: 20210340181Abstract: The present invention provides peptides and peptide-conjugates that bind to ?v?6 integrin. The peptide-conjugates can be used for a variety of imaging and therapeutic applications. Methods of use and peptide optimization are also provided herein.Type: ApplicationFiled: March 3, 2021Publication date: November 4, 2021Applicant: The Regents of the University of CaliforniaInventors: Yng Tang, Julie L. Sutcliffe
-
Publication number: 20210206804Abstract: The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.Type: ApplicationFiled: December 22, 2020Publication date: July 8, 2021Applicant: The Regents of the University of CaliforniaInventors: Sven H. Hausner, Julie L. Sutcliffe
-
Patent number: 10919932Abstract: The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.Type: GrantFiled: October 13, 2016Date of Patent: February 16, 2021Assignee: The Regents of the University of CaliforniaInventors: Sven H. Hausner, Julie L. Sutcliffe
-
Publication number: 20190328910Abstract: The present invention provides peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates comprise a moiety such as a PEG moiety, an imaging agent, or a therapeutic agent. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue. Compositions and kits containing the peptide conjugates of the present invention are also provided herein.Type: ApplicationFiled: December 12, 2018Publication date: October 31, 2019Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Yng Tang, Julie L. Sutcliffe
-
Publication number: 20170174723Abstract: The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.Type: ApplicationFiled: October 13, 2016Publication date: June 22, 2017Applicant: The Regents of the University of CaliforniaInventors: Sven H. Hausner, Julie L. Sutcliffe
-
Publication number: 20160368993Abstract: The present invention provides isolated, engineered multivalent antibody fragments that specifically bind ?V?6 integrin. In particular embodiments, the antibody fragments of the present invention further comprise an imaging agent and/or a therapeutic agent. In some instances, the antibody fragments also include unnatural amino acids and/or inserted cysteine or thiol residues at the C-terminus of the scFv molecules of the fragments. The anti-?V?6 integrin antibody fragments provided herein are particularly useful for imaging a tumor, organ or tissue and for treating an ?V?6 integrin-mediated disease or disorder. Compositions and kits containing the multivalent antibody fragments of the present invention are also described herein.Type: ApplicationFiled: June 2, 2016Publication date: December 22, 2016Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Julie L. Sutcliffe, JASON BRADLEY WHITE